×
MaxCyte EBIT 2020-2024 | MXCT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
MaxCyte ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
MaxCyte EBIT 2020-2024 | MXCT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
MaxCyte ebit from 2020 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$151.4B
Bristol Myers Squibb (BMY)
$119.8B
Gilead Sciences (GILD)
$119.1B
Vertex Pharmaceuticals (VRTX)
$113.7B
CSL (CSLLY)
$83.5B
Regeneron Pharmaceuticals (REGN)
$75.5B
GSK (GSK)
$72.7B
Argenex SE (ARGX)
$39.5B
Alnylam Pharmaceuticals (ALNY)
$35.3B
BioNTech SE (BNTX)
$29B
BeiGene (ONC)
$22.2B
Biogen (BIIB)
$21B
Illumina (ILMN)
$20.9B
Moderna (MRNA)
$15.7B
Incyte (INCY)
$14.2B
Insmed (INSM)
$14B
Intra-Cellular Therapies (ITCI)
$13.5B
Genmab (GMAB)
$13.1B
Genmab (GNMSF)
$12.9B
BioMarin Pharmaceutical (BMRN)
$12.1B
Bio-Techne Corp (TECH)
$11.4B
Vaxcyte (PCVX)
$11.1B
Sarepta Therapeutics (SRPT)
$11B
Exact Sciences (EXAS)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Bio-Rad Laboratories (BIO.B)
$10B
QIAGEN (QGEN)
$9.7B
Repligen (RGEN)
$9.5B
Exelixis (EXEL)
$9.4B
Roivant Sciences (ROIV)
$8.1B